CliffBio
small molecule

ALPHAGAN P

BRIMONIDINE TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameALPHAGAN P
Active ingredientBRIMONIDINE TARTRATE
Strength0.1%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2005
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ALPHAGAN P patent cliff — loss of exclusivity — | CliffBio